KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-6979 |   Pharmaceuticals

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET

7.1 GLOBAL KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA KIDNEY CANCER AND RENAL CELL CARCINOMA (RCC) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Cipla Limited

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Glaxosmithkline Plc

16.3 Amgen

16.4 F. Hoffmann-La Roche Ag

16.5 Pfizer, Inc.

16.6 Bayer AG

16.7 Onyx

16.8 Genentech, Inc.

16.9 Active Biotech Ab

16.10 Novartis Ag

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Most important types of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs products covered in this report are:
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)

Most widely used downstream fields of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market covered in this report are:
Renal cell carcinoma (RCC)
Transitional cell carcinoma (TCC)

Companies

Cipla Limited
Glaxosmithkline Plc
Amgen
F. Hoffmann-La Roche Ag
Pfizer, Inc.
Bayer AG
Onyx
Genentech, Inc.
Active Biotech Ab
Novartis Ag

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.